Dexrazoxane for Preventing Anthracycline Cardiotoxicity in Children with Solid Tumors.
10.3346/jkms.2010.25.9.1336
- Author:
Hyoung Soo CHOI
1
;
Eun Sil PARK
;
Hyoung Jin KANG
;
Hee Young SHIN
;
Chung Il NOH
;
Yong Soo YUN
;
Hyo Seop AHN
;
Jung Yun CHOI
Author Information
1. Department of Pediatrics, Seoul National University Bundang Hospital, Sungnam, Korea. choi3628@snu.ac.kr
- Publication Type:Original Article ; Controlled Clinical Trial ; Research Support, Non-U.S. Gov't
- Keywords:
Dexrazoxane;
Doxorubicin;
Cardiotoxicity;
Child;
Solid Tumors
- MeSH:
Adolescent;
Antibiotics, Antineoplastic/*adverse effects;
Cardiomyopathies/chemically induced/prevention & control;
Cardiovascular Agents/*therapeutic use;
Child;
Child, Preschool;
Cohort Studies;
Disease-Free Survival;
Doxorubicin/*adverse effects;
Echocardiography;
Female;
Follow-Up Studies;
Heart Failure/chemically induced/prevention & control;
Humans;
Infant;
Male;
Neoplasms/*drug therapy/mortality;
Razoxane/*therapeutic use;
Ventricular Function, Left/physiology
- From:Journal of Korean Medical Science
2010;25(9):1336-1342
- CountryRepublic of Korea
- Language:English
-
Abstract:
This study attempted to assess the incidence and outcome of anthracycline cardiotoxicity and the role of dexrazoxane as a cardioprotectant in childhood solid tumors. The dexrazoxane group included 47 patients and the control group of historical cohort included 42. Dexrazoxane was given in the 10:1 ratio to doxorubicin. Fractional shortening and systolic and diastolic left ventricular diameters were used to assess the cardiac function. The median follow-ups were 54 months in the dexrazoxane group and 86 months in the control group. The mean cumulative doses of doxorubicin were 280.8+/-83.4 mg/m2 in the dexrazoxane group and 266.1+/-75.0 mg/m2 in the control group. The dexrazoxane group experienced significantly fewer cardiac events (27.7% vs. 52.4%) and less severe congestive heart failure (6.4% vs. 14.3%) than the control group. Thirteen cardiotoxicities including one cardiac death and 2 congestive heart failures occurred in the dexrazoxane group, and 22 cardiotoxicities including 2 cardiac deaths and 4 congestive heart failures, in the control group. Five year cardiac event free survival rates were 69.2% in the dexrazoxane group and 45.8% in the control group (P=0.04). Dexrazoxane reduces the incidence and severity of early and late anthracycline cardiotoxicity in childhood solid tumors.
